HESI members present at the World Congress on Alternatives and Animal Use in the Life Sciences.
World Congress on Alternatives and Animal Use in the Life Sciences
August 27, 2023 – August 31, 2023
Niagara Falls, Canada
The mission of HESIās Emerging Systems Toxicology for the Assessment of Risk (eSTAR) Committee is to develop and deliver innovative systems toxicology approaches for risk assessment. The committee aims to catalyze adoption of new translational and predictive tools that guide decision-making based on mechanistic understanding of toxicological response.
This project is developing transcriptomic-based biomarkers that will be predictive of particular molecular initiating events leading to rat liver tumors. The group has also launched an experimental study in wildtype & knockout rats for molecular initiating events.
This Consortium has initiated the design and implementation of a pioneering experimental study to advance integration of in vitro āomics approaches (Cell Painting, transcriptomics, and proteomics) into safety evaluation. The Massachusetts Life Sciences Center (MLSC) grant has been awarded to our nonprofit partner, the Broad Institute, at $1,000,000! Matched with contributions from our 16 industry partners, we expect a total project budget of approximately $4.2 million.
This group is exploring the use of error corrected sequencing to identify non-genotoxic tumorigenic agents in rodents. An inventory of samples from members was compiled that can be used to measure cancer driver genes. A pilot study has been completed comparing study designs to detect clonal expansion.
This team designed a study looking at the effect of different nephrotoxicants on multiple miRNAs using an in vitro model for proximal tubule cells. They also conducted a multi-site experimental program on the use of exosomal miRNAs expressed in response to renal toxicants; manuscript published in 2024.
This group was awarded a $250,000 USD grant (U01) as part of the US FDAās Biomarker Qualification Program in 2022. This funding was partnered with Committee resources to support a four-site ring trial generating additional data on the TGx-DDI biomarker. Submission package is being prepared for qualification and the group is exploring other opportunities such as the OECD Test Guideline process.
Learn more about the use of the TGx-DDI transcriptomic biomarker for the genotoxicity assessment of data-poor chemicals here (poster presented at the 2021 EMGS Virtual Annual Meeting by Anne-Marie Fortin, University of Ottawa).
This Working Group has compiled a broad membership of experts across sectors and chemical classes to write a recently accepted manuscript on the state of the science on the use and potential applications of transcriptomic PODs. Future work will include discussion of bioinformatic methods to derive transcriptomic PODs.
FFPE Project: A manuscript on DNA de-modification analysis of clinical tumor samples was accepted; the project will sunset after an educational webinar.
National Institute of Environmental Health Sciences
Syngenta
August 27, 2023 – August 31, 2023
Niagara Falls, Canada
HESI members present at the World Congress on Alternatives and Animal Use in the Life Sciences.
May 16, 2013 – May 17, 2013
Paris, France
This workshop was held on 16-17 May 2013 at OECD Congress Center in Paris, France, with the goal to review progress in human carcinogenesis safety evaluation strategies and cancer risk assessment.
May 25, 2017 – May 26, 2017
Montreal, Canada
This is a 2-day workshop co-organized by the Health and Environmental Sciences Institute, Health Canada, and McGill University to address current and potential applications of genomics in cancer risk assessment.
November 21, 2024
HESI OASIS Consortium Members Presenting, eSTAR Committee
Join HESI OASIS Consortium members David Rouquie (Bayer) and Jessica Ewald (Broad Institute) for an exciting installment of the DyNAMic Discussions webinar series, where experts share their experiences in overcoming barriers to applying New Approach Methodologies (NAMs) in their fields. This seminar series offers candid ...
February 23, 2023
eSTAR, Physicians Committee for Responsible Medicine Webinar Series
The eSTAR committee will be presenting as part of the Physicians Committee for Responsible Medicine Webinar Series called "Tomorrow's Data, Today: Sunsetting the 2-year Carcinogenicity Assay".
November 18, 2013
Washington, District of Columbia, USA
The HESI eSTAR Committee hosted a workshop on epigenetics and its potential implication for toxicology.
No results.
The Emerging Systems Toxicology for the Assessment of Risk (eSTAR) CommitteeĀ is part of the Center for Translational Sciences. This HESI Center serves as a focal point for staff to share strategic approaches, scientific developments, management best practices and innovations with other related HESI committees.
Other Committees in the Center for Translational Sciences are:
For questions about the Center contact:
hesi@hesiglobal.org
Phone: +1-202-659-8404
Fax: +1-202-659-8403
740 15th Street NW, Suite 600
Washington, DC 20005
Sign up for our monthly e-newsletter.